MDXHealth
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
19 sep 2007 - 10:31
Statutaire naam
MDXHealth
Titel
OncoMethylome’s Colorectal Cancer Screening Test Demonstrates High Performance in Clinical Trials
Bericht
Liege (Belgium) – September 19, 2007, 8:00am CET – OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) published new data from its colorectal cancer program at the AACR conference on Molecular Diagnostics in Cancer Therapeutic Development. OncoMethylome showed that it has successfully identified methylation markers that, when combined in a test panel, are very accurate in detecting early-stage colorectal cancer via stool samples.
The new methylation markers are the result of OncoMethylome’s own marker-discovery activities. The markers demonstrated strong performance in detecting early-stage cancer in stool samples collected from people with all stages of colorectal cancer. When combined in a test panel, the markers detected early-stage colorectal cancer with 86% sensitivity and 96% specificity. In other words, the test correctly detected 86% of early-stage colon cancers, and it correctly identified, as non-cancerous, 96% of controls consisting of stool collected from healthy, age-appropriate, people.
Gerelateerde downloads
Datum laatste update: 22 december 2025